Processa Pharmaceuticals (PCSA) FCF Margin (2012 - 2016)
Processa Pharmaceuticals' (PCSA) quarterly FCF Margin came in at 878.0% in Q1 2016, up 20334.0% YoY from N/an in Q2 2015, and up 49.15% on a QoQ basis from 1726.59% in Q4 2015.
Processa Pharmaceuticals (PCSA) FCF Margin (2012 - 2016) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 5 years of FCF Margin data on file, last reported at 878.0% in Q1 2016.
- Quarterly FCF Margin rose 20334.0% year-over-year to 878.0% in Q1 2016, while the trailing twelve-month figure through Dec 2016 was 617.06% (up 37654.0% YoY) and the FY2016 annual result came in at 617.06%, up 15288.0% from the prior year.
- FCF Margin grew to 878.0% in Q1 2016, from 1726.59% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 158.33% in Q3 2015 to a low of 7763.64% in Q1 2014.
- A 5-year average of 1778.59% and a median of 1045.56% in 2014 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2014 — FCF Margin slumped 464255 bps — and 2015, when it soared 668230 bps.
- Tracing PCSA's FCF Margin over 5 years: stood at 2105.51% in 2012, then jumped by 69 bps to 659.92% in 2013, then tumbled by 364 bps to 3061.53% in 2014, then soared by 44 bps to 1726.59% in 2015, then jumped by 49 bps to 878.0% in 2016.
- The last three FCF Margin figures came in at 878.0% (Q1 2016), 1726.59% (Q4 2015), and 158.33% (Q3 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -878.00% |
| Dec 31, 2015 | -1,726.59% |
| Sep 30, 2015 | -158.33% |
| Jun 30, 2015 | -943.36% |
| Mar 31, 2015 | -1,081.34% |
| Dec 31, 2014 | -3,061.53% |
| Sep 30, 2014 | -1,045.56% |
| Jun 30, 2014 | -922.19% |
| Mar 31, 2014 | -7,763.64% |
| Dec 31, 2013 | -659.92% |
| Sep 30, 2013 | -579.51% |
| Jun 30, 2013 | -796.66% |
| Mar 31, 2013 | -3,121.09% |
| Dec 31, 2012 | -2,105.51% |
| Sep 30, 2012 | -1,835.63% |